Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and$291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and$93.8 million, respectively NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and full year ended December ...